特发性肺纤维化患者FVC变异性及6分钟步行试验预测进一步变化的作用
研究基于954例IPF患者(3966次观察)的3期试验数据,分析3个月内FVC变化的变异性;同期FVC与6MWD下降(1321次观察)可预测随后3个月FVC的进一步下降。
要点
- IPF患者FVC下降速率个体间高度变异,既往下降对后续下降预测能力差。
- 3个月内FVC与6MWD同期下降可预测随后3个月FVC进一步下降。
- FVC占预计值百分比绝对或相对下降≥10%与死亡率相关。
核心结论
- IPF患者FVC变化个体间高度变异,既往下降对后续FVC下降预测能力差。
- 同期3个月内FVC与6MWD下降可预测随后3个月FVC的进一步下降。
研究设计与样本
- 基于3期试验数据,纳入954例IPF患者,共3966次FVC观察。
- 其中1321次观察同时包含FVC与6MWD的3个月变化数据。
主要发现
- IPF患者FVC随时间呈现显著变异,既往下降不能良好预测未来FVC下降。
- 3个月内FVC与6MWD同期下降可预测随后3个月FVC进一步下降。
关键数值与推荐
- FVC占预计值百分比绝对或相对下降≥10%与死亡率相关。
- 既往试验安慰剂组FVC下降幅度为130–210 mL,背景抗纤维化治疗下新试验可检测的下降幅度约70 mL。
临床怎么用
- 监测IPF疾病进展时需考虑FVC变化的变异性,单次下降不宜过度解读。
- 可结合3个月内FVC与6MWD同期变化评估后续FVC下降风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Variability in 3-month changes in FVC was examined in 954 patients with IPF (n=3966 observations) from phase 3 trials; concurrent 3-month decline in the FVC and 6MWD (n=1321 observations) predicted further decline in FVC over the subsequent 3 months http://bit.ly/2GfBKW3 Disease progression in idiopathic pulmonary fibrosis (IPF) is monitored by decline in forced vital capacity (FVC) [1]. An absolute or relative decline in % predicted FVC ≥10% is associated with mortality [2, 3]. Measures of FVC decline were selected as primary endpoints in the pivotal phase 3 trials of antifibrotic therapies [4–6]. Despite consistent trends for FVC decline in the IPF population, the rate of disease progression in individuals is unpredictable and highly variable: significant variability in FVC is observed over time, and prior declines are a poor predictor of future FVC decline [1, 7, 8]. In new trials in IPF, the margin for reducing FVC decline is smaller (∼70 mL) in patients who are receiving an investigational drug with background antifibrotics than in the placebo arms of past trials (130–210 mL) [9].
引用
- Nathan SD, Yang M, Morgenthien EA, et al. FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. Eur Respir J. 2020. PMID: 32029447. doi:10.1183/13993003.02151-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。